➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Boehringer Ingelheim
McKinsey
Johnson and Johnson
AstraZeneca

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRIAMCINOLONE ACETATE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Triamcinolone Acetate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00148265 ↗ A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema Completed Marsden Eye Centre Phase 2/Phase 3 2005-04-01 This study is likely to identify an improved and economical treatment for diabetic macular oedema, one of the commonest causes of blindness both in Australia and the rest of the world.The specific aims of the study are to test the following hypotheses: - That intravitreal triamcinolone followed by laser treatment results in a greater improvement in visual acuity than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in greater degree of resolution of macular oedema than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in a reduced requirement for further laser treatment to control diabetic macular oedema than placebo followed by laser treatment; - That intravitreal triamcinolone followed laser has a manageable and acceptable safety profile in eyes with diabetic macular edema.
NCT00148265 ↗ A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema Completed The University of Western Australia Phase 2/Phase 3 2005-04-01 This study is likely to identify an improved and economical treatment for diabetic macular oedema, one of the commonest causes of blindness both in Australia and the rest of the world.The specific aims of the study are to test the following hypotheses: - That intravitreal triamcinolone followed by laser treatment results in a greater improvement in visual acuity than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in greater degree of resolution of macular oedema than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in a reduced requirement for further laser treatment to control diabetic macular oedema than placebo followed by laser treatment; - That intravitreal triamcinolone followed laser has a manageable and acceptable safety profile in eyes with diabetic macular edema.
NCT00148265 ↗ A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema Completed University of Melbourne Phase 2/Phase 3 2005-04-01 This study is likely to identify an improved and economical treatment for diabetic macular oedema, one of the commonest causes of blindness both in Australia and the rest of the world.The specific aims of the study are to test the following hypotheses: - That intravitreal triamcinolone followed by laser treatment results in a greater improvement in visual acuity than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in greater degree of resolution of macular oedema than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in a reduced requirement for further laser treatment to control diabetic macular oedema than placebo followed by laser treatment; - That intravitreal triamcinolone followed laser has a manageable and acceptable safety profile in eyes with diabetic macular edema.
NCT00148265 ↗ A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema Completed University of Sydney Phase 2/Phase 3 2005-04-01 This study is likely to identify an improved and economical treatment for diabetic macular oedema, one of the commonest causes of blindness both in Australia and the rest of the world.The specific aims of the study are to test the following hypotheses: - That intravitreal triamcinolone followed by laser treatment results in a greater improvement in visual acuity than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in greater degree of resolution of macular oedema than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in a reduced requirement for further laser treatment to control diabetic macular oedema than placebo followed by laser treatment; - That intravitreal triamcinolone followed laser has a manageable and acceptable safety profile in eyes with diabetic macular edema.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Triamcinolone Acetate

Condition Name

Condition Name for Triamcinolone Acetate
Intervention Trials
Diabetic Macular Oedema 3
Macular Edema 2
Glaucoma 2
Glucocorticoids 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Triamcinolone Acetate
Intervention Trials
Macular Edema 7
Edema 5
Retinal Vein Occlusion 2
Glaucoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Triamcinolone Acetate

Trials by Country

Trials by Country for Triamcinolone Acetate
Location Trials
United States 11
Brazil 4
Spain 3
Australia 3
Egypt 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Triamcinolone Acetate
Location Trials
California 5
New York 2
Maryland 1
Florida 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Triamcinolone Acetate

Clinical Trial Phase

Clinical Trial Phase for Triamcinolone Acetate
Clinical Trial Phase Trials
Phase 4 4
Phase 3 2
Phase 2/Phase 3 7
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Triamcinolone Acetate
Clinical Trial Phase Trials
Completed 8
Recruiting 4
Unknown status 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Triamcinolone Acetate

Sponsor Name

Sponsor Name for Triamcinolone Acetate
Sponsor Trials
University of Sydney 3
Goldman, Butterwick, Fitzpatrick and Groff 2
Alcon Research 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Triamcinolone Acetate
Sponsor Trials
Other 25
Industry 5
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
AstraZeneca
Moodys
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.